Ultragenyx to Sell FDA Priority Review Voucher for $203 Million
Ultragenyx entered an asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $203 million in cash at closing. The voucher was awarded after FDA approval of FAYUVI (UX111) for MPS IIIA. The transaction is subject to customary conditions.
Ultragenyx Pharmaceutical entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash at closing. The voucher was awarded by the FDA on Sep 17 2026 following approval of FAYUVI (UX111) for MPS IIIA. The transaction is subject to customa…